ArticleMolecular carcinogenesis2026
The 5-Methylcytosine RNA Modification in Hepatitis B Virus-Negative Hepatocellular Carcinoma: Insights From Long-Read Nanopore Sequencing.
Article in Molecular carcinogenesis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The 5-Methylcytosine RNA Modification in Hepatitis B Virus-Negative Hepatocellular Carcinoma: Insights From Long-Read Nanopore Sequencing.Molecular carcinogenesis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
5-Methylcytosine (m5C) RNA modification contributes to tumor initiation and progression. However, its transcriptome-wide distribution patterns and biological implications in hepatitis B virus (HBV)-negative hepatocellular carcinoma (HCC) remain poorly understood. Therefore, this study employs long-read Nanopore direct RNA sequencing to systematically elucidate the mechanisms of m5C-mediated epigenetic reprogramming in HBV-negative HCC. Paired tumor and adjacent normal tissues from three HBV-negative HCC patients were collected for Nanopore sequencing. Transcriptome-wide m5C sites were profiled using the CHEUI tool, followed by a comprehensive comparison between tumor and adjacent normal tissue groups regarding the number of m5C sites, their genomic distribution characteristics, and the expression levels of m5C regulators. Finally, an integrated analysis of transcriptomic and methylation data was conducted to identify m5C-related prognostic indicators in HCC. Tumor tissues exhibited a global increase in m5C sites abundance, with differential modifications enriched on chromosomes 1-3. Genes harboring m5C modifications were significantly enriched in immune and inflammatory pathways, suggesting a potential role for this epitranscriptomic mark in remodeling the tumor immune microenvironment. Consistent upregulation of m5C regulators, including NSUN family members and ALYREF, at both gene and isoform levels, correlated with increased methylation activity. Elevated m5C coupled with decreased CES3 expression were associated with poorer overall survival. Additionally, TMEM234 showed prognostic significance despite unchanged bulk expression in public datasets. m5C modifications are globally altered in HBV-negative HCC and may contribute to post-transcriptional regulation and aberrant expression. These findings highlight the potential of m5C as both a prognostic biomarker and a therapeutic target in HBV-negative HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.